{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124636","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.529070+00:00","generated_at":"2026-05-30T02:20:39.830529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CG Oncology Q3 net loss $20.4M; cash $540.7M, runway through 2027","bullets":["Net loss of $20.4M ($0.30 per share) vs $17.5M ($4.00) in Q3 2023.","Cash and securities $540.7M as of Sept 30, 2024; expects to fund operations through 2027.","R&D expenses $19.6M (up from $11.7M) driven by clinical trial and CMC costs.","G&A expenses $8.7M (up from $2.3M) due to personnel, professional fees, insurance.","Phase 3 BOND-003 cretostimogene results accepted as late-breaking abstract at SUO 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124636","json":"https://secwatch.observer/filing/0000950170-24-124636.json","markdown":"https://secwatch.observer/filing/0000950170-24-124636.md","text":"https://secwatch.observer/filing/0000950170-24-124636.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000095017024124636/0000950170-24-124636-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000095017024124636/ck0001991792-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:20:39.830529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}